Top Markets
#1 PulseChain PulseChain +45.01%
#2 Glidr Glidr +20.14%
#3 Fake World Assets Fake World Assets +9.76%
#4 Ergo Ergo +9.25%
#5 eCash eCash +8.85%
#6 DeFi Kingdoms DeFi Kingdoms +8.68%
#7 Ribbita by Virtuals Ribbita by Virtuals +8.32%
#8 Meteora Meteora +8.28%
#9 Verus Coin Verus Coin +7.70%
#10 Cash Cat Cash Cat +7.22%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
AgeX Therapeutics, Inc. AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc.

AGE
Rank in Stocks #28237
AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to... AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to pioneering and commercializing groundbreaking therapies that address human aging and degenerative conditions. The company's developmental pipeline features several promising cell-based therapeutic candidates: AGEX-BAT1: A cell therapy designed to manage various age-related metabolic disorders, including adult-onset Type II diabetes and obesity. AGEX-VASC1: A cell-based approach aimed at re-establishing vital vascular support in aged ischemic tissues, which could be relevant for conditions such as peripheral vascular disease and ischemic heart disease. Beyond cell therapies, AgeX is also exploring other modalities: Its primary drug candidate in the discovery phase is AGEX-iTR1547, a drug formulation focused on achieving scarless wound repair. For induced tissue regeneration, its leading biologic candidate is AGEX-iTR1550, which leverages gene delivery technology. Furthermore, AgeX maintains a research collaboration with the University of California at Irvine, jointly working to develop cellular therapies for various neurological disorders. Founded in 2017, AgeX Therapeutics, Inc. maintains its headquarters in Alameda, California.
Share Price
$11.10
Last synced: 2024-03-26
Market Cap
$27.76M
Change (1 day)
-11.90%
Change (1 year)
0.00%
Country
US
Trade AgeX Therapeutics, Inc. (AGE)

Category

Healthcare
P/E ratio for AgeX Therapeutics, Inc. (AGE)
P/E ratio as of 2026 TTM: 0
According to AgeX Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for AgeX Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.